<DOC>
	<DOCNO>NCT02646501</DOCNO>
	<brief_summary>The investigator compare effect PSGB ( percutaneous stellate ganglion block ) patient recurrent sustain VT/VF spite appropriate medical therapy cardio-version/ defibrillation correction underlie correctable factor without PSGB prospective randomize trail . PSGB perform every 3 day anesthesiology specialist cardiologist 's request , stabilization VT/VF . We compare frequency episode number VT/VF , procedure relate complication , acute long-term mortality .</brief_summary>
	<brief_title>Prospective Randomized Clinical Trial Effect Stellate Ganglion Block Medically Refractory Ventricular Tachycardia</brief_title>
	<detailed_description>Recurrent ventricular tachycardia ( VT ) / fibrillation ( VF ) increase mortality , especially patient structural heart disease . It report cardiac sympathectomy reduces VT/VF episodes patient complex VT , long QT syndrome , catecholaminergic polymorphic VT , myocarditis . However , cardiac sympathectomy operation hard conduct patient hemodynamically unstable recurrent VT/VF electrical storm . Therefore , hypothesize bed-side percutaneous stellate ganglion block ( PSGB ) reduce VT/VF episode mortality patient repetitive VT/VF properly manage optimal medical therapy .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Ventricular</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Patients agreement consent AF patient age 2085 Patient diagnose Refractory Ventricular tachycardia Patients generate Refractory Ventricular tachycardia despite defibrillation drug therapy Patients ICD generate ICD shock antitachycardia pace despite defibrillation drug therapy Patients agree study inclusion Patients take stellate ganglion block due unstable hemodynamic status Patients experience major hemorrhagic complication Patients DNR status Patients malignancy tumor , major neurogenic disease gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>